Clinical Trial Update: Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine [Phase 3]

View source ↗

Summary

A Phase 3 immunogenicity study comparing GlaxoSmithKline's Hib-MenC conjugate vaccine to a licensed meningococcal C vaccine; it assesses primary and booster imm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilus Influenzae Type Infection
• Meningococcal Disease

Drugs mentioned

• Hib-MenC conjugate vaccine (Haemophilus influenzae type b and Neisseria meningitidis serogroup C conjugate vaccine)
• Licensed meningococcal C vaccine (Meningococcal group C conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 3 | Status: COMPLETED